Share：
Share this content in WeChat
X
[Chinese][PDF]4212
• Clinical Article •
Research on the evaluation of the liver function grading for the patients with hepatitis B cirrhosis using T1 mapping based extracellular volume fraction
XU Hui  LI Yaguang  MU Jiankui  YAN Zijia  HAN Xiaonan  LEI Licun 

Cite this article as: XU H, LI Y G, MU J K, et al. Research on the evaluation of the liver function grading for the patients with hepatitis B cirrhosis using T1 mapping based extracellular volume fraction[J]. Chin J Magn Reson Imaging, 2023, 14(5): 132-138. DOI:10.12015/issn.1674-8034.2023.05.023.


[Abstract] Objective To evaluate the research value of the extracellular volume fraction (ECV) in evaluating the liver function grading [Child-Pugh grade and albumin-bilirubin (ALBI) grade] for the patients with chronic hepatitis B cirrhosis, and to explore the ECV value difference among various liver function grading groups.Materials and Methods The patients that all received the gadobenate dimeglumine (Gd-BOPTA) enhanced MRI examination in the First Hospital of Hebei Medical University from January to October 2022 were selected, which all included the laboratory test results within two weeks before or after the MRI examination. A total of 67 cases of patients were included, with 17 cases in normal liver function (NLF) group and 50 cases in the cirrhosis group. The T1 mapping including the plain scan and balance phases was performed on all of these patients, and the T1 values of the patients' liver parenchyma and abdominal aorta in the plain scan and balance phases were measured, based on which, in combination with the hematocrit levels, the ECV values were calculated. The patients of the cirrhosis group were divided into a Child-Pugh grade group and an ALBI grade group as per the two liver function grading methods. The Spearman correlation coefficient was used to analyze the correlation between the ECV values and the scores as a result of the liver function scoring models such as ALBI grade and Child-Pugh grade. The one-way analysis of variance was used to compare the differences of the ECV values among the groups. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of the ECV values in identifying the patients of the different liver function groups, and the cut-off values, sensitivity, specificity and area under the curve (AUC) were calculated.Results There was a significant positive correlation between the ECV values and the grades of the Child-Pugh grade (r=0.694, P＜0.01) and those of the ALBI grade (r=0.689, P＜0.01), and the ECV values increased with the increase of the liver function grading (Child-Pugh grade, and ALBI grade). There was a significant difference in the ECV values between the patients of the Child-Pugh grade group and those of the ALBI grade group (P＜0.01). In the case of the Child-Pugh grade group, the AUCs of the ECV identification of NLF vs. CP-A, CP-A vs. CP-B and CP-B vs. CP-C were 0.82, 0.78 and 0.84, respectively. In the case of the ALBI grade group, the AUCs of the ECV identification of NLF vs. ALBI 1, ALBI 1 vs. ALBI 2 and ALBI 2 vs. ALBI 3 were 0.79, 0.70 and 0.91, respectively.Conclusions The ECV value based on the T1 mapping is a reliable index for evaluating the liver function of the patients with chronic hepatitis B cirrhosis. The diagnostic efficacy of the ALBI grading in evaluating the liver function of the patients with chronic hepatitis B cirrhosis is comparable to that of the Child-Pugh grading, but it is simpler and more objective, and therefore can be used as a complement to the Child-Pugh grading.
[Keywords] liver cirrhosis；liver function；albumin-bilirubin grade；Child-Pugh grade；T1 mapping；extracellular volume fraction；magnetic resonance imaging

XU Hui1   LI Yaguang1   MU Jiankui1   YAN Zijia1   HAN Xiaonan2   LEI Licun1*  

1 Departent of Radiology and Nuclear Medicine, the First Hospital of Hebei Medical University, Shijiazhuang 050031, China

2 Departent of Radiology, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China

Corresponding author: Lei LC, E-mail: 312660114@qq.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Hebei Province Medical Science Research Project (No. 20231013).
Received  2022-12-30
Accepted  2023-05-06
DOI: 10.12015/issn.1674-8034.2023.05.023
Cite this article as: XU H, LI Y G, MU J K, et al. Research on the evaluation of the liver function grading for the patients with hepatitis B cirrhosis using T1 mapping based extracellular volume fraction[J]. Chin J Magn Reson Imaging, 2023, 14(5): 132-138. DOI:10.12015/issn.1674-8034.2023.05.023.

[1]
ASRANI S K, DEVARBHAVI H, EATON J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70(1): 151-171. DOI: 10.1016/j.jhep.2018.09.014">10.1016/j.jhep.2018.09.014">10.1016/j.jhep.2018.09.014.
[2]
PIMPIN L, CORTEZ-PINTO H, NEGRO F, et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies[J]. J Hepatol, 2018, 69(3): 718-735. DOI: 10.1016/j.jhep.2018.05.011">10.1016/j.jhep.2018.05.011">10.1016/j.jhep.2018.05.011.
[3]
SEBASTIANI G, GKOUVATSOS K, PANTOPOULOS K. Chronic hepatitis C and liver fibrosis[J]. World J Gastroenterol, 2014, 20(32): 11033-11053. DOI: 10.3748/wjg.v20.i32.11033">10.3748/wjg.v20.i32.11033">10.3748/wjg.v20.i32.11033.
[4]
National Health Commission of the People's Republic of China. China health statistics yearbook-2020[M]. Beijing: Peking Union Medical College Press, 2020.
[5]
Chinese Society of Infectious Diseases of Chinese Medical Association, Chinese Society of Hepatology of Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2019 version)[J]. Chin J Clin Infect Dis, 2019, 12(6): 401-428. DOI: 10.3760/cma.j.issn.1674-2397.2019.06.001">10.3760/cma.j.issn.1674-2397.2019.06.001">10.3760/cma.j.issn.1674-2397.2019.06.001.
[6]
ROCKEY D C, CALDWELL S H, GOODMAN Z D, et al. Liver biopsy[J]. Hepatology, 2009, 49(3): 1017-1044. DOI: 10.1002/Hep.22742">10.1002/Hep.22742">10.1002/Hep.22742.
[7]
EVERETT R J, STIRRAT C G, SEMPLE S I R, et al. Assessment of myocardial fibrosis with T1 mapping MRI[J]. Clin Radiol, 2016, 71(8): 768-778. DOI: 10.1016/j.crad.2016.02.013">10.1016/j.crad.2016.02.013">10.1016/j.crad.2016.02.013.
[8]
FRIEDLI I, CROWE L A, BERCHTOLD L, et al. New magnetic resonance imaging index for renal fibrosis assessment: a comparison between diffusion-weighted imaging and T1 mapping with histological validation[J/OL]. Sci Rep, 2016, 6: 30088 [2023-04-25]. https://www.nature.com/articles/srep30088. DOI: 10.1038/srep30088">10.1038/srep30088">10.1038/srep30088.
[9]
MESSROGHLI D R, MOON J C, FERREIRA V M, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)[J/OL]. J Cardiovasc Magn Reson, 2017, 19(1): 75 [2023-04-25]. https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-017-0389-8#citeas. DOI: 10.1186/s12968-017-0389-8">10.1186/s12968-017-0389-8">10.1186/s12968-017-0389-8.
[10]
XU X Y, DING H G, LI W G, et al. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006">10.3969/j.issn.1001-5256.2019.11.006">10.3969/j.issn.1001-5256.2019.11.006.
[11]
JOHNSON P J, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6): 550-558. DOI: 10.1200/JCO.2014.57.9151">10.1200/JCO.2014.57.9151">10.1200/JCO.2014.57.9151.
[12]
FAHLENKAMP U L, KUNKEL J, ZIEGELER K, et al. Correlation of native liver parenchyma T1 and T2 relaxation times and liver synthetic function tests: a pilot study[J/OL]. Diagnostics (Basel), 2021, 11(6): 1125 [2023-04-25]. https://www.mdpi.com/2075-4418/11/6/1125. DOI: 10.3390/diagnostics11061125">10.3390/diagnostics11061125">10.3390/diagnostics11061125.
[13]
OKUBO H, ANDO H, SORIN Y, et al. Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C[J/OL]. PLoS One, 2018, 13(4): e0196747 [2023-04-25]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196747. DOI: 10.1371/journal.pone.0196747">10.1371/journal.pone.0196747">10.1371/journal.pone.0196747.
[14]
KUPCZYK P A, MESROPYAN N, ISAAK A, et al. Quantitative MRI of the liver: evaluation of extracellular volume fraction and other quantitative parameters in comparison to MR elastography for the assessment of hepatopathy[J]. Magn Reson Imaging, 2021, 77: 7-13. DOI: 10.1016/j.mri.2020.12.005">10.1016/j.mri.2020.12.005">10.1016/j.mri.2020.12.005.
[15]
VARENIKA V, FU Y J, MAHER J J, et al. Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT[J]. Radiology, 2013, 266(1): 151-158. DOI: 10.1148/radiol.12112452">10.1148/radiol.12112452">10.1148/radiol.12112452.
[16]
BENEDETTI N, ASLAM R, WANG Z J, et al. Delayed enhancement of ascites after i.v. contrast material administration at CT: time course and clinical correlation[J]. AJR Am J Roentgenol, 2009, 193(3): 732-737. DOI: 10.2214/AJR.08.1929">10.2214/AJR.08.1929">10.2214/AJR.08.1929.
[17]
LEPORQ B, DAIRE J L, PASTOR C M, et al. Quantification of hepatic perfusion and hepatocyte function with dynamic gadoxetic acid-enhanced MRI in patients with chronic liver disease[J]. Clin Sci (Lond), 2018, 132(7): 813-824. DOI: 10.1042/CS20171131">10.1042/CS20171131">10.1042/CS20171131.
[18]
CHEN R C, CAI Y J, WU J M, et al. Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis[J]. J Viral Hepat, 2017, 24(3): 238-245. DOI: 10.1111/jvh.12638">10.1111/jvh.12638">10.1111/jvh.12638.
[19]
MESROPYAN N, KUPCZYK P, KUKUK G M, et al. Diagnostic value of magnetic resonance parametric mapping for non-invasive assessment of liver fibrosis in patients with primary sclerosing cholangitis[J/OL]. BMC Med Imaging, 2021, 21(1): 65 [2023-04-25]. https://bmcmedimaging.biomedcentral.com/articles/10.1186/s12880-021-00598-0. DOI: 10.1186/s12880-021-00598-0.
[20]
LUETKENS J A, KLEIN S, TRÄBER F, et al. Quantification of liver fibrosis at T1 and T2 mapping with extracellular volume fraction MRI: preclinical results[J]. Radiology, 2018, 288(3): 748-754. DOI: 10.1148/radiol.2018180051">10.1148/radiol.2018180051">10.1148/radiol.2018180051.
[21]
LUETKENS J A, KLEIN S, TRAEBER F, et al. Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study[J]. Gut, 2018, 67(3): 593-594. DOI: 10.1136/gutjnl-2017-314561">10.1136/gutjnl-2017-314561">10.1136/gutjnl-2017-314561.
[22]
SAHIN S, ROWLAND M. Estimation of aqueous distributional spaces in the dual perfused rat liver[J]. J Physiol, 2000, 528(Pt 1): 199-207. DOI: 10.1111/j.1469-7793.2000.00199">10.1111/j.1469-7793.2000.00199">10.1111/j.1469-7793.2000.00199.
[23]
SHENG R F, JIN K P, WANG H Q, et al. Study on diagnostic value of extracellular volume imaging by magnetic resonance imaging for liver fibrosis of hepatitis B[J]. Chin J Hepatol, 2018, 26(9): 650-653. DOI: 10.3760/cma.j.issn.1007-3418.2018.09.003">10.3760/cma.j.issn.1007-3418.2018.09.003">10.3760/cma.j.issn.1007-3418.2018.09.003.
[24]
WANG H Q, JIN K P, ZENG M S, et al. Assessing liver fibrosis in chronic hepatitis B using MR extracellular volume measurements: comparison with serum fibrosis indices[J]. Magn Reson Imaging, 2019, 59: 39-45. DOI: 10.1016/j.mri.2019.03.002">10.1016/j.mri.2019.03.002">10.1016/j.mri.2019.03.002.
[25]
MESROPYAN N, KUPCZYK P A, DOLD L, et al. Assessment of liver cirrhosis severity with extracellular volume fraction MRI[J/OL]. Sci Rep, 2022, 12(1): 9422 [2023-04-25]. https://www.nature.com/articles/s41598-022-13340-9. DOI: 10.1038/s41598-022-13340-9">10.1038/s41598-022-13340-9">10.1038/s41598-022-13340-9.
[26]
BREIT H C, BLOCK K T, WINKEL D J, et al. Evaluation of liver fibrosis and cirrhosis on the basis of quantitative T1 mapping: are acute inflammation, age and liver volume confounding factors?[J/OL]. Eur J Radiol, 2021, 141: 109789 [2023-04-25]. https://linkinghub.elsevier.com/retrieve/pii/S0720-048X(21)00270-9. DOI: 10.1016/j.ejrad.2021.109789">10.1016/j.ejrad.2021.109789">10.1016/j.ejrad.2021.109789.
[27]
WONG M, BUSUTTIL R W. Surgery in patients with portal hypertension[J]. Clin Liver Dis, 2019, 23(4): 755-780. DOI: 10.1016/j.cld.2019.07.003">10.1016/j.cld.2019.07.003">10.1016/j.cld.2019.07.003.
[28]
CHOLONGITAS E, PAPATHEODORIDIS G V, VANGELI M, et al. Systematic review: the model for end-stage liver disease: should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?[J]. Aliment Pharmacol Ther, 2005, 22(11/12): 1079-1089. DOI: 10.1111/j.1365-2036.2005.02691">10.1111/j.1365-2036.2005.02691">10.1111/j.1365-2036.2005.02691.
[29]
D'AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies[J]. J Hepatol, 2006, 44(1): 217-231. DOI: 10.1016/j.jhep.2005.10.013">10.1016/j.jhep.2005.10.013">10.1016/j.jhep.2005.10.013.
[30]
WANG J, ZHANG Z P, YAN X M, et al. Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis[J]. Dig Liver Dis, 2019, 51(8): 1172-1178. DOI: 10.1016/j.dld.2019.01.011">10.1016/j.dld.2019.01.011">10.1016/j.dld.2019.01.011.
[31]
TOYODA H, JOHNSON P. The ALBI score: from liver function in patients with HCC to a general measure of liver function[J/OL]. JHEP Rep, 2022, 4(10):100557 [2023-04-25]. https://www.jhep-reports.eu/article/S2589-5559(22)00129-X/fulltext. DOI: 10.1016/J.Jhepr.2022.100557">10.1016/J.Jhepr.2022.100557">10.1016/J.Jhepr.2022.100557.
[32]
REN X, LIU A L, ZHAO Y. Application progress of hepatobiliary specific contrast agent MRI in diffuse disease of the liver[J]. Chin J Magn Reson Imaging, 2022, 13(6): 151-154, 159. DOI: 10.12015/issn.1674-8034.2022.06.032">10.12015/issn.1674-8034.2022.06.032">10.12015/issn.1674-8034.2022.06.032.
[33]
BRISMAR T B, DAHLSTROM N, EDSBORG N, et al. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers[J]. Acta Radiol, 2009, 50(7): 709-715. DOI: 10.1080/02841850903055603">10.1080/02841850903055603">10.1080/02841850903055603.
[34]
LEWIS S, VASUDEVAN P, CHATTERJI M, et al. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors[J]. Abdom Radiol (NY), 2016, 41(7): 1300-1309. DOI: 10.1007/s00261-016-0693-z">10.1007/s00261-016-0693-z">10.1007/s00261-016-0693-z.
[35]
Pediatric Group of Chinese Society of Radiology of Chinese Medical Association, Radiology Group of Chinese Society of Pediatric of Chinese Medical Association. Chinese expert consensus on contrast agent gadobenate dimeglumine for enhanced MRI of center nervous system in children[J]. Chin J Radiol, 2019, 53(5): 329-335. DOI: 10.3760/cma.j.issn.1005-1201.2019.05.001">10.3760/cma.j.issn.1005-1201.2019.05.001">10.3760/cma.j.issn.1005-1201.2019.05.001.
[36]
CATUCCI D, OBMANN V C, BERZIGOTTI A, et al. Noninvasive assessment of clinically significant portal hypertension using ΔT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI[J/OL]. Eur J Radiol, 2021, 144: 109958 [2023-04-25]. https://www.ejradiology.com/article/S0720-048X(21)00439-3/fulltext. DOI: 10.1016/j.ejrad.2021.109958">10.1016/j.ejrad.2021.109958">10.1016/j.ejrad.2021.109958.
[37]
LI Z M, SUN J H, HU X, et al. Assessment of liver fibrosis by variable flip angle T1 mapping at 3.0T[J]. J Magn Reson Imaging, 2016, 43(3): 698-703. DOI: 10.1002/jmri.25030">10.1002/jmri.25030">10.1002/jmri.25030.

PREV Multi-center study on the prognostic value of cardiac magnetic resonance feature tracking technique for MACE after percutaneous coronary intervention in patients with acute myocardial infarction during hospitalization
NEXT Comparison of 3D amide proton transfer imaging and intravoxel incoherent motion imaging in the diagnosis of prostate cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn